CA2500713A1 - Photokinetic delivery of biologically active substances using pulsed incoherent light - Google Patents

Photokinetic delivery of biologically active substances using pulsed incoherent light Download PDF

Info

Publication number
CA2500713A1
CA2500713A1 CA002500713A CA2500713A CA2500713A1 CA 2500713 A1 CA2500713 A1 CA 2500713A1 CA 002500713 A CA002500713 A CA 002500713A CA 2500713 A CA2500713 A CA 2500713A CA 2500713 A1 CA2500713 A1 CA 2500713A1
Authority
CA
Canada
Prior art keywords
group
composition according
light
tyr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002500713A
Other languages
French (fr)
Other versions
CA2500713C (en
Inventor
Edward R. Kraft
Gabriela Kulp
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PHOTOKINETIX HOLDINGS Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2500713A1 publication Critical patent/CA2500713A1/en
Application granted granted Critical
Publication of CA2500713C publication Critical patent/CA2500713C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0042—Photocleavage of drugs in vivo, e.g. cleavage of photolabile linkers in vivo by UV radiation for releasing the pharmacologically-active agent from the administered agent; photothrombosis or photoocclusion
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions

Abstract

The invention relates generally to transdermal and transmembrane delivery of biologically active substances through the skin, sub-dermal tissues, blood vessels and cellular membranes without causing damage to the cellular membrane surface, tissue or membrane. The invention provides compositions and methods for enhanced transdermal and transmembrane delivery of biologically active substances using pulsed incoherent light. The invention further provides a device for the application of the pulsed incoherent light to cellular surfaces and membranes using those compositions and methods.

Claims (61)

1. A composition for photokinetic delivery of a biologically active substance using pulsed incoherent light, comprising a biologically active substance, a solvent, a gelling agent and a photocatalytic agent, wherein said photocatalytic agent has a band gap energy of between about 2.9 eV and about 3.2 eV.
2. The composition according to claim 1 wherein said photocatalytic agent is present in said composition at a concentration of between 0.001% and 20% (w/w).
3. The composition according to claim 2 wherein said photocatalytic agent is present in said composition at a concentration of 2% (w/w).
4. The composition according to claim 1 wherein said biologically active substance is present in said composition at a concentration of between about 0.01% and about 2% (w/v).
5. The composition according to claim 1 wherein said gelling agent is present in said composition at a concentration of between 0.1% and 10%
(w/v).
6. The composition according to claim 1 wherein said biologically active substance is selected from the group consisting of chemicals, drugs, antibiotics, peptides, hormones, proteins, DNA, RNA and mixtures thereof.
7. The composition according to claim 6 wherein said chemical is a polar or non-polar compound.
8. The composition according to claim 7 wherein said polar compound is selected from the group consisting of theophylline-7 acetic acid, sodium ascorbyl phosphate, ascorbic acid, ascorbyl palmitate, pyridoxine and nicotinic acid.
9. The composition according to claim 8 wherein said polar compound is pyridoxine.
10. The composition according to claim 7 wherein said non-polar compound is selected from the group consisting of theobromine, theophylline, caffeine and nicotinamide.
11. The composition according to claim 6 wherein said drug is selected from the group consisting of analgesics, anaesthetics, antacids, antianxiety drugs, antiarrhythmics, antibacterials, antibiotics, anticoagulants and thrombolytics, anticonvulsants, antidepressants, antidiarrheals, antiemetics, antifungals, antihistamines, antihypertensives, anti-inflammatories, antieoplastics, antipsychotics, antipyretics, antivirals, barbiturates, beta-blockers, bronchodilators, cold cures, corticosteroids, cough suppressants, cytotoxics, decongestants, diuretics, expectorants, hormones, hypoglycemics, immunosuppressives, laxatives, muscle relaxants, sedatives, sex hormones, sleeping drugs, tranquilizers and vitamins.
12. The composition according to claim 11 wherein said anaesthetic is lidocaine.
13. The composition according to claim 6 wherein said peptide is selected from the group consisting of Gly-Tyr, Val-Tyr-Val, Tyr-Gly-Gly-Phe-Met, Tyr-Gly-Gly-Phe-Leu and Asp-Arg-Val-Tyr-Ile-His-Pro-Phe.
14. The composition according to claim 6 wherein said hormone is selected from the group consisting of methionine enkephalin acetate, leucine enkephalin, angiotensin II acetate, .beta.-estradiol, methyl testosterone, progesterone and insulin.
15. The composition according to claim 6 wherein said protein is selected from the group consisting of enzymes, non-enzymes, antibodies and glycoproteins.
16. The composition according to claim 6 wherein said antibiotic is amphotericin B.
17. The composition according to claim 1 wherein said gelling agent is selected from the group consisting of hydroxyethyl cellulose, Natrasol®, pectines, agar, alginic acid and its salts, guar gum, pectin, polyvinyl alcohol, polyethylene oxide, cellulose and its derivatives, propylene carbonate, polyethylene glycol, hexylene glycol sodium carboxymethylcellulose, polyacrylates, polyoxyethylene-polyoxypropylene block copolymers, pluronics, wood wax alcohols and tyloxapol.
18. The composition according to claim 17 wherein said gelling agent is hydroxypropyl cellulose.
19. The composition according to claim 1 wherein said photocatalytic agent is a rutile form of titanium dioxide.
20. The composition according to claim 1 wherein said photocatalytic agent is selected from the group consisting of an anatase form of titanium dioxide, brookite form of titanium dioxide, ZnO, ZrO2 and Sc2O3.
21. The composition according to claim 1 wherein said solvent is an aqueous or an organic solvent.
22. The composition according to claim 21 wherein said aqueous solvent is water.
23. The composition according to claim 21 wherein said aqueous solvent is an aqueous solution of ethyl lactate or propylene glycol.
24. A method of photokinetic delivery comprising:
preparing a solution comprising a biologically active substance and a solvent;
applying said solution to a cellular surface;
illuminating said solution on said cellular surface with a pulsed incoherent light having a selected wavelength, pulse rate and duty cycle; and allowing said solution to permeate said cellular surface.
25. The method according to claim 24 wherein said solution further comprises a gelling agent.
26. The method according to claim 24 wherein said solution further comprises a photocatalytic agent.
27. The method according to claim 24 wherein said biologically active substance is selected from the group consisting of chemicals, drugs, antibiotics, peptides, hormones, proteins, DNA, RNA and mixtures thereof.
28. The method according to claim 27 wherein said chemicals comprise a polar or a non-polar compound.
29. The method according to claim 28 wherein said polar compound is selected from the group consisting of theophylline-7 acetic acid, sodium ascorbyl phosphate, ascorbic acid, ascorbyl palmitate, pyridoxine, nicotinic acid and lidocaine.
30. The method according to claim 28 wherein said non-polar compound is selected from the group consisting of theobromine, theophylline, caffeine and nicotinamide.
31. The method according to claim 27 wherein said drug is selected from the group consisting of analgesics, anaesthetics, antacids, antianxiety drugs, antiarrhythmics, antibacterials, antibiotics, anticoagulants and thrombolytics, anticonvulsants, antidepressants, antidiarrheals, antiemetics, antifungals, antihistamines, antihypertensives, anti-inflammatories, antieoplastics, antipsychotics, antipyretics, antivirals, barbiturates, beta-blockers, bronchodilators, cold cures, corticosteroids, cough suppressants, cytotoxics, decongestants, diuretics, expectorant, hormones, hypoglycemics, immunosuppressives, laxatives, muscle relaxants, sedatives, sex hormones, sleeping drugs, tranquilizer and vitamins.
32. The method according to claim 27 wherein said peptide is selected from the group consisting of Gly-Tyr, Val-Tyr-Val, Tyr-Gly-Gly-Phe-Met, Tyr-Gly-Gly-Phe-Leu and Asp-Arg-Val-Tyr-Ile-His-Pro-Phe.
33. The method according to claim 27 wherein said hormone is selected from the group consisting of methionine enkephalin acetate, leucine enkephalin, angiotensin II acetate, .beta.-estradiol, methyl testosterone and progesterone.
34. The method according to claim 27 wherein said protein is selected from the group consisting of enzymes, non-enzymes, antibodies and glycoproteins.
35. The method according to claim 24 wherein said gelling agent is selected from the group consisting of hydroxyethyl cellulose, Natrasol®, pectines, agar, alginic acid and its salts, guar gum, pectin, polyvinyl alcohol, polyethylene oxide, cellulose and its derivatives, propylene carbonate, polyethylene glycol, hexylene glycol sodium carboxymethylcellulose, polyacrylates, polyoxyethylene-polyoxypropylene block copolymers, pluronics, wood wax alcohols and tyloxapol.
36. The method according to claim 24 wherein said photocatalytic agent has a band gap energy of between about 2.9 eV and about 3.2 eV.
37. The method according to claim 24 wherein said photocatalytic agent is a rutile form of titanium dioxide.
38. The method according to claim 24 wherein said photocatalytic agent is an anatase form of titanium dioxide.
39. The method according to claim 24 wherein said solvent is an aqueous or an organic solvent.
40. The method according to claim 39 wherein said aqueous solvent is water.
41. The method according to claim 39 wherein said aqueous solvent is an aqueous solution of ethyl lactate or propylene glycol.
42. The method according to claim 24 wherein said cellular surface is an outer layer of a skin of a mammal.
43. The method according to claim 24 wherein said cellular surface is a cell membrane.
44. The method according to claim 24 wherein said pulsed incoherent light is selected from the group consisting of fluorescent, ultraviolet, visible, near infrared and halogen light.
45. The method according to claim 44 wherein said fluorescent light has a wavelength range from about 260 nm to about 760 nm.
46. The method according to claim 44 wherein said ultraviolet light has a wavelength range from about 340 nm to about 900 nm.
47. The method according to claim 44 wherein said visible light has a wavelength range from about 340 nm to about 900 nm.
48. The method according to claim 44 wherein said near infrared light has a wavelength range from about 340 nm to about 900 nm.
49. The method according to claim 44 wherein said halogen light has a wavelength range from about 340 nm to about 900 nm.
50. The method according to claim 24 wherein said wavelength is selected from the group consisting of 350 nm, 390 nm, 405 nm and 450 nm.
51. The method according to claim 24 wherein said pulse rate is between about 1.7 cps and about 120 cps.
52. The method according to claim 51 wherein said pulse rate is between about 1.7 cps and about 80 cps.
53. The method according to claim 24 wherein said duty cycle is between about 50% and about 75%.
54. A device for photokinetic transdermal delivery, said device comprising:
a generator that provides an oscillating electrical pulse;
at least one light emitting diode that receives the oscillating electrical pulse and responds by providing an incoherent light; and a donor cell that holds a solution comprising a biologically active substance and a solvent; wherein:
the donor cell is positioned to receive the incoherent light.
55. The device according to claim 54 wherein said generator is a repeat cycle square wave pulse generator.
56. The device according to claim 54 further comprising a light pad, wherein at least one light emitting diode is embedded in said light pad.
57. The device according to claim 56 wherein said light pad is comprised of an optically clear material.
58. The device according to claim 57 wherein said optically clear material is poly(methyl-methacrylate) or silicone rubber.
59. The device according to claim 54 wherein said light emitting diode emits a light having a wavelength selected from the group consisting of 350 nm, 390 nm, 405 nm and 450 nm.
60. The device according to claim 54 wherein said solution further comprises a gelling agent.
61. The device according to claim 54 wherein said solution further comprises a photocatalytic agent.
CA2500713A 2002-10-04 2003-10-03 Photokinetic delivery of biologically active substances using pulsed incoherent light Expired - Lifetime CA2500713C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US41636102P 2002-10-04 2002-10-04
US60/416,361 2002-10-04
US47950103P 2003-06-17 2003-06-17
US60/479,501 2003-06-17
PCT/US2003/031532 WO2004032963A2 (en) 2002-10-04 2003-10-03 Photokinetic delivery of biologically active substances using pulsed incoherent light

Publications (2)

Publication Number Publication Date
CA2500713A1 true CA2500713A1 (en) 2004-04-22
CA2500713C CA2500713C (en) 2012-07-03

Family

ID=32096146

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2500713A Expired - Lifetime CA2500713C (en) 2002-10-04 2003-10-03 Photokinetic delivery of biologically active substances using pulsed incoherent light

Country Status (7)

Country Link
US (2) US7458982B2 (en)
EP (1) EP1556061B1 (en)
AT (1) ATE359802T1 (en)
AU (1) AU2003282683A1 (en)
CA (1) CA2500713C (en)
DE (1) DE60313353T2 (en)
WO (1) WO2004032963A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6219575B1 (en) * 1998-10-23 2001-04-17 Babak Nemati Method and apparatus to enhance optical transparency of biological tissues
US20130274837A1 (en) * 1998-10-23 2013-10-17 Babak Nemati Systems and Methods to Enhance Optical Transparency of Biological Tissues for Photobiomodulation
DE602004019514D1 (en) * 2003-05-09 2009-04-02 Philips Intellectual Property TREATMENT DEVICE USING SEMICONDUCTOR LIGHT DIODES
GB0525072D0 (en) * 2005-12-09 2006-01-18 Enigma Diagnostics Ltd Fluorescence-based detection methods and apparatus
US20080031833A1 (en) * 2006-03-13 2008-02-07 Oblong John E Combined energy and topical composition application for regulating the condition of mammalian skin
KR101258336B1 (en) 2008-10-02 2013-04-25 밀란 인크. Method of making a multilayer adhesive laminate
HUP0900073A2 (en) * 2009-02-06 2010-11-29 Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag Process and equipment for inquiry medical product on dermal surface
US8523791B2 (en) * 2009-08-11 2013-09-03 Laboratoire Naturel Paris, Llc Multi-modal drug delivery system
EP2485765A2 (en) * 2009-10-09 2012-08-15 Board Of Regents The University Of Texas System Photokinetic ocular drug delivery methods and apparatus
WO2012130336A1 (en) * 2011-03-29 2012-10-04 Principium Europe S.R.L. Delivery of large molecular weight biologically active substances
WO2013078422A2 (en) 2011-11-23 2013-05-30 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10206932B2 (en) 2014-05-22 2019-02-19 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations
US11701527B2 (en) 2020-08-31 2023-07-18 B/E Aerospace, Inc. Enclosed system environment pressure regulator
WO2023034682A1 (en) * 2021-09-01 2023-03-09 Lumeda Inc. Optical surface applicator with forward and backward projection

Family Cites Families (136)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5135477A (en) * 1984-10-29 1992-08-04 Medtronic, Inc. Iontophoretic drug delivery
US4702732A (en) * 1984-12-24 1987-10-27 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation and transdermal delivery of pharmacologically active ligands
US4886489A (en) * 1986-03-19 1989-12-12 Jacobsen Stephen C Flow-through methods and apparatus for iontophoresis application of medicaments at a controlled pH
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US5961482A (en) 1986-07-25 1999-10-05 Rutgers, The State University Of New Jersey Iontotherapeutic device and process and iontotherapeutic unit dose
US4786277A (en) * 1986-11-21 1988-11-22 Trustees Of Boston University Electrodes, electrode assemblies, methods, and systems for tissue stimulation
US4940456A (en) * 1987-02-10 1990-07-10 Dan Sibalis Electrolytic transdermal delivery of proteins
US5080646A (en) * 1988-10-03 1992-01-14 Alza Corporation Membrane for electrotransport transdermal drug delivery
US4931046A (en) * 1987-05-15 1990-06-05 Newman Martin H Iontophoresis drug delivery system
US5749847A (en) * 1988-01-21 1998-05-12 Massachusetts Institute Of Technology Delivery of nucleotides into organisms by electroporation
US5156846A (en) * 1989-02-23 1992-10-20 University Of Utah Percutaneous drug delivery system
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
US5084008A (en) * 1989-12-22 1992-01-28 Medtronic, Inc. Iontophoresis electrode
US5047007A (en) * 1989-12-22 1991-09-10 Medtronic, Inc. Method and apparatus for pulsed iontophoretic drug delivery
US5016615A (en) * 1990-02-20 1991-05-21 Riverside Research Institute Local application of medication with ultrasound
US5231975A (en) * 1990-02-23 1993-08-03 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
US5115805A (en) * 1990-02-23 1992-05-26 Cygnus Therapeutic Systems Ultrasound-enhanced delivery of materials into and through the skin
AU657681B2 (en) * 1990-03-30 1995-03-23 Alza Corporation Device and method for iontophoretic drug delivery
US6004309A (en) * 1990-03-30 1999-12-21 Alza Corporation Method and apparatus for controlled environment electrotransport
US5125894A (en) * 1990-03-30 1992-06-30 Alza Corporation Method and apparatus for controlled environment electrotransport
US5362308A (en) * 1990-09-25 1994-11-08 Rutgers, The State University Of New Jersey Disposable dosage unit for iontophoresis-facilitated transdermal delivery, related devices and processes
US6139537A (en) * 1990-11-01 2000-10-31 Tapper; Robert Iontophoretic treatment system
US5224927A (en) * 1990-11-01 1993-07-06 Robert Tapper Iontophoretic treatment system
US6238381B1 (en) 1990-11-01 2001-05-29 Robert Tapper Iontophoretic treatment system
US6235013B1 (en) * 1990-11-01 2001-05-22 Robert Tapper Iontophoretic treatment system
DK0563085T3 (en) * 1990-12-19 1996-12-16 Beecham Group Plc Hitherto unknown preparations
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5207998A (en) * 1991-05-07 1993-05-04 Richardson-Vicks Inc. Suncare compositions
US5203768A (en) * 1991-07-24 1993-04-20 Alza Corporation Transdermal delivery device
US5464387A (en) 1991-07-24 1995-11-07 Alza Corporation Transdermal delivery device
US6024968A (en) * 1991-08-16 2000-02-15 Lincoln Technologies Inc. Intersorption composition and method
US5258453A (en) * 1992-01-21 1993-11-02 University Of Utah Drug delivery system for the simultaneous delivery of drugs activatable by enzymes and light
DE69320378T2 (en) 1992-01-21 1999-04-29 Macrochem Corp Iontophoretic improved drug delivery
FR2688106B1 (en) * 1992-02-27 1994-09-09 Lhd Lab Hygiene Dietetique DEVICE FOR GENERATING AN PREDETERMINED WAVEFORM ELECTRIC VOLTAGE, IONOPHORETIC APPARATUS FOR TRANSDERMAL DELIVERY OF MEDICAMENTS.
GB2265088B (en) * 1992-03-10 1996-02-07 Kyosti Eero Antero Kontturi Electrochemical device for drug delivery
US6009345A (en) * 1992-08-17 1999-12-28 Genetronics, Inc. Method and apparatus for a combination of electroporation and iontophoresis for the delivery of drugs and genes
US5306235A (en) * 1992-09-30 1994-04-26 Becton Dickinson And Company Failsafe iontophoresis drug delivery system
US5421816A (en) * 1992-10-14 1995-06-06 Endodermic Medical Technologies Company Ultrasonic transdermal drug delivery system
GB2272278B (en) * 1992-10-23 1997-04-09 Cancer Res Campaign Tech Light source
US6315772B1 (en) * 1993-09-24 2001-11-13 Transmedica International, Inc. Laser assisted pharmaceutical delivery and fluid removal
AU681376B2 (en) * 1993-01-13 1997-08-28 Miravant Systems, Inc. Light emitting diode source for photodynamic therapy
US5527350A (en) * 1993-02-24 1996-06-18 Star Medical Technologies, Inc. Pulsed infrared laser treatment of psoriasis
US5667487A (en) * 1993-04-07 1997-09-16 Henley; Julian L. Ionosonic drug delivery apparatus
TW360548B (en) * 1993-04-08 1999-06-11 Powderject Res Ltd Products for therapeutic use
US5533971A (en) 1993-09-03 1996-07-09 Alza Corporation Reduction of skin irritation during electrotransport
US5814599A (en) * 1995-08-04 1998-09-29 Massachusetts Insitiute Of Technology Transdermal delivery of encapsulated drugs
US5885211A (en) * 1993-11-15 1999-03-23 Spectrix, Inc. Microporation of human skin for monitoring the concentration of an analyte
ES2117861T3 (en) * 1994-03-30 1998-08-16 Alza Corp REDUCTION OF SKIN IRRITATION DURING THE ADMINISTRATION OF MEDICINES BY ELECTRIC TRANSPORT.
JPH09511927A (en) * 1994-04-18 1997-12-02 ザ、プロクター、エンド、ギャンブル、カンパニー Iontophoretic delivery of bisphosphonates to alveolar bone
GB2289236B (en) * 1994-05-09 1997-08-06 Boucherie Nv G B A brush making machine
US6048545A (en) * 1994-06-24 2000-04-11 Biozone Laboratories, Inc. Liposomal delivery by iontophoresis
US5771890A (en) * 1994-06-24 1998-06-30 Cygnus, Inc. Device and method for sampling of substances using alternating polarity
WO1996002232A1 (en) * 1994-07-13 1996-02-01 Alza Corporation Composition and method for enhancing transdermal electrotransport agent delivery
US5540654A (en) * 1994-09-02 1996-07-30 North Carolina State University Iontophoretic electrode
US5817144A (en) 1994-10-25 1998-10-06 Latis, Inc. Method for contemporaneous application OF laser energy and localized pharmacologic therapy
US5736580A (en) * 1994-11-14 1998-04-07 Alza Croporation Composition, device, and method for electrotransport agent delivery
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US5700481A (en) * 1995-03-17 1997-12-23 Takeda Chemical Industries, Ltd. Transdermal drug delivery process
US5843014A (en) * 1995-03-24 1998-12-01 Alza Corporation Display for an electrotransport delivery device
US6425892B2 (en) * 1995-06-05 2002-07-30 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6216033B1 (en) * 1996-05-22 2001-04-10 Alza Corporation Device for transdermal electrotransport delivery of fentanyl and sufentanil
US6041253A (en) * 1995-12-18 2000-03-21 Massachusetts Institute Of Technology Effect of electric field and ultrasound for transdermal drug delivery
US5947921A (en) * 1995-12-18 1999-09-07 Massachusetts Institute Of Technology Chemical and physical enhancers and ultrasound for transdermal drug delivery
US6002961A (en) * 1995-07-25 1999-12-14 Massachusetts Institute Of Technology Transdermal protein delivery using low-frequency sonophoresis
US5698207A (en) * 1995-07-26 1997-12-16 International Laboratory Technology Corp. Burn treatment composition
US6167301A (en) * 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
US5964749A (en) * 1995-09-15 1999-10-12 Esc Medical Systems Ltd. Method and apparatus for skin rejuvenation and wrinkle smoothing
US20070185552A1 (en) * 1996-02-13 2007-08-09 Leonardo Masotti Device and method for biological tissue stimulation by high intensity laser therapy
FR2747313B1 (en) * 1996-04-16 1998-06-05 Lhd Lab Hygiene Dietetique TRANSDERMAL MEDICINE DELIVERY DEVICE BY IONOPHORESIS
US6385487B1 (en) * 1996-05-08 2002-05-07 Biophoretic Therapeutic Systems, Llc Methods for electrokinetic delivery of medicaments
WO1997048444A1 (en) * 1996-06-19 1997-12-24 Becton Dickinson And Company Iontophoretic delivery of cell adhesion inhibitors
EP0813887A3 (en) * 1996-06-20 1999-11-03 Hisamitsu Pharmaceutical Co. Inc. A device structure for iontophoresis
JP2002515786A (en) * 1996-06-28 2002-05-28 ソントラ メディカル，エル．ピー． Ultrasound enhancement of transdermal delivery
BR9603084A (en) * 1996-07-12 1998-05-05 Cosmeticos Natural Ind Com Dry emulsion composition for skin
US6106514A (en) * 1996-08-12 2000-08-22 O'donnell, Jr.; Francis E. Laser method for subsurface cutaneous treatment
US5947821A (en) * 1996-10-01 1999-09-07 Casino Data Systems Card game
US6024717A (en) * 1996-10-24 2000-02-15 Vibrx, Inc. Apparatus and method for sonically enhanced drug delivery
CA2272647A1 (en) * 1996-11-27 1998-06-04 Shun K. Lee Compound delivery using impulse transients
US6050990A (en) * 1996-12-05 2000-04-18 Thermolase Corporation Methods and devices for inhibiting hair growth and related skin treatments
US5999678A (en) 1996-12-27 1999-12-07 Eclipse Surgical Technologies, Inc. Laser delivery means adapted for drug delivery
US6085115A (en) * 1997-05-22 2000-07-04 Massachusetts Institite Of Technology Biopotential measurement including electroporation of tissue surface
US5954675A (en) * 1997-07-07 1999-09-21 Dellagatta; Enrico Michael Method of ultrasonic therapy
US6436127B1 (en) * 1997-10-08 2002-08-20 The General Hospital Corporation Phototherapy methods and systems
GB9721506D0 (en) * 1997-10-10 1997-12-10 Virulite Limited Treatment of diseases
TW368420B (en) * 1997-11-04 1999-09-01 Genetronics Inc Apparatus and method for transdermal molecular delivery by applying sufficient amplitude of electric field to induce migration of molecules through pores in the stratum corneum
US6071944A (en) * 1997-11-12 2000-06-06 Bowling Green State University Method of treatment of pigmented cancer cells utilizing photodynamic therapy
US6295469B1 (en) * 1997-11-14 2001-09-25 Alza Corporation Formulation for electrically assisted delivery of lidocaine and epinephrine
US5941821A (en) * 1997-11-25 1999-08-24 Trw Inc. Method and apparatus for noninvasive measurement of blood glucose by photoacoustics
USRE37796E1 (en) * 1997-12-16 2002-07-23 Biophoretic Therapeutic Systems, Llc Methods for iontophoretic delivery of antiviral agents
US6235381B1 (en) * 1997-12-30 2001-05-22 The Boeing Company Reinforced ceramic structures
WO1999034868A1 (en) * 1998-01-07 1999-07-15 Kim Robin Segal Diode laser irradiation and electrotherapy system for biological tissue stimulation
EP1045714A1 (en) * 1998-01-08 2000-10-25 Sontra Medical, L.P. Sonophoretic enhanced transdermal transport
US6221068B1 (en) * 1998-01-15 2001-04-24 Northwestern University Method for welding tissue
US6165170A (en) * 1998-01-29 2000-12-26 International Business Machines Corporation Laser dermablator and dermablation
US6059736A (en) * 1998-02-24 2000-05-09 Tapper; Robert Sensor controlled analysis and therapeutic delivery system
US6398753B2 (en) * 1998-04-03 2002-06-04 Mcdaniel David H. Ultrasound enhancement of percutaneous drug absorption
US6030374A (en) * 1998-05-29 2000-02-29 Mcdaniel; David H. Ultrasound enhancement of percutaneous drug absorption
US6322532B1 (en) * 1998-06-24 2001-11-27 3M Innovative Properties Company Sonophoresis method and apparatus
US6148231A (en) * 1998-09-15 2000-11-14 Biophoretic Therapeutic Systems, Llc Iontophoretic drug delivery electrodes and method
WO2000024455A1 (en) * 1998-10-28 2000-05-04 Cygnus, Inc. Kit and method for quality control testing of an iontophoretic sampling system
US6283956B1 (en) * 1998-11-30 2001-09-04 David H. McDaniels Reduction, elimination, or stimulation of hair growth
JP2000237230A (en) * 1999-02-17 2000-09-05 Kyoshin Shoji Co Ltd Photocatalyst fixing adhesive tape
US6389313B1 (en) * 1999-03-26 2002-05-14 Kevin S. Marchitto Laser probes for drug permeation
US6379324B1 (en) * 1999-06-09 2002-04-30 The Procter & Gamble Company Intracutaneous microneedle array apparatus
US20040122492A1 (en) * 1999-07-07 2004-06-24 Yoram Harth Phototherapeutic treatment of skin conditions
US6669951B2 (en) * 1999-08-24 2003-12-30 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into epithelial tissues
US6421561B1 (en) * 1999-12-30 2002-07-16 Birch Point Medical, Inc. Rate adjustable drug delivery system
US6904073B2 (en) 2001-01-29 2005-06-07 Cymer, Inc. High power deep ultraviolet laser with long life optics
US7450618B2 (en) * 2001-01-30 2008-11-11 Board Of Trustees Operating Michigan State University Laser system using ultrashort laser pulses
ES2252383T3 (en) * 2001-02-27 2006-05-16 JOHNSON & JOHNSON CONSUMER FRANCE SAS AGENTS TO PONTENTIATE PRESERVANTS IN SOLAR FILTER FORMULATIONS.
DE10208678A1 (en) 2001-03-09 2002-09-12 Henkel Kgaa Polyurethane foam product for cosmetic or dermatological use comprises the in situ reaction product of a urethane prepolymer with an aqueous dispersion containing selected active ingredients
CA2445898A1 (en) * 2001-05-01 2002-12-19 The General Hospital Corporation Photoimmunotherapies for cancer using photosensitizer immunoconjugates and combination therapies
EP1414516A2 (en) * 2001-06-26 2004-05-06 Photomed Technologies, Inc. Therapeutic methods using electromagnetic radiation
GB0127581D0 (en) * 2001-11-17 2002-01-09 Univ St Andrews Therapeutic Light-emitting device
AUPS051002A0 (en) * 2002-02-14 2002-03-07 Riancorp Pty Ltd Low level laser therapy method and means
US20030191458A1 (en) 2002-04-03 2003-10-09 Cornelius Diamond Light-activated drug delivery method and device
US20040073277A1 (en) * 2002-04-05 2004-04-15 Geronemus Roy G. High fluence rate activation of photosensitizers for dermatological applications
IL150914A (en) * 2002-07-25 2014-04-30 Zamir Tribelsky Method for hydro-optronic photochemical treatment of liquids
US20040048842A1 (en) * 2002-09-10 2004-03-11 Mcmillan Kathleen Method of treating skin disorders
US7931028B2 (en) * 2003-08-26 2011-04-26 Jay Harvey H Skin injury or damage prevention method using optical radiation
EP1581305A2 (en) 2002-12-20 2005-10-05 Palomar Medical Technologies, Inc. Apparatus for light treatment of acne and other disorders of follicles
US7250045B2 (en) * 2003-02-25 2007-07-31 Spectragenics, Inc. Self-contained, eye-safe hair-regrowth-inhibition apparatus and method
WO2004093993A1 (en) 2003-04-23 2004-11-04 Qlt Inc. Hair growth
US20050010271A1 (en) * 2003-07-07 2005-01-13 Merchant Robert F. Method of using radiation to treat cutaneous and sub-cutaneous conditions
CA2437638A1 (en) * 2003-08-20 2005-02-20 John Robert North Photodynamic therapy
US20050203593A1 (en) * 2003-10-24 2005-09-15 Shanks Steven C. Method for dermatology therapies in combination with low level laser treatments
DE602004032400D1 (en) * 2003-11-05 2011-06-01 Photobiomed Corp Connecting tissues and crosslinking proteins with naphthalimide compounds
JP4971133B2 (en) 2004-04-01 2012-07-11 ザ ジェネラル ホスピタル コーポレイション Equipment for dermatological treatment
US20050245998A1 (en) 2004-04-30 2005-11-03 Led Healing Light, Llc Hand held pulse laser for therapeutic use
US8109981B2 (en) 2005-01-25 2012-02-07 Valam Corporation Optical therapies and devices
US20060173514A1 (en) * 2005-02-02 2006-08-03 Advanced Photodynamic Technologies, Inc. Wound treatment device for photodynamic therapy and method of using same
EP1933941A2 (en) 2005-08-25 2008-06-25 Philip R. Houle Treatment systems for delivery of sensitizer solutions
US20070219600A1 (en) * 2006-03-17 2007-09-20 Michael Gertner Devices and methods for targeted nasal phototherapy
WO2007122611A2 (en) * 2006-04-20 2007-11-01 Nano Pass Technologies Ltd. Device and methods combining vibrating micro-protrusions with phototherapy
US20080234669A1 (en) * 2007-03-19 2008-09-25 Kauvar Arielle N B Method and device for treating skin by superficial coagulation
US20090012515A1 (en) * 2007-07-06 2009-01-08 Hoenig Peter A Devices, systems and methods for treating tissues

Also Published As

Publication number Publication date
EP1556061B1 (en) 2007-04-18
WO2004032963A9 (en) 2005-04-28
AU2003282683A8 (en) 2004-05-04
WO2004032963A3 (en) 2004-12-16
EP1556061A2 (en) 2005-07-27
DE60313353D1 (en) 2007-05-31
CA2500713C (en) 2012-07-03
WO2004032963A2 (en) 2004-04-22
AU2003282683A1 (en) 2004-05-04
US20040131687A1 (en) 2004-07-08
US7854753B2 (en) 2010-12-21
ATE359802T1 (en) 2007-05-15
US20090156463A1 (en) 2009-06-18
US7458982B2 (en) 2008-12-02
DE60313353T2 (en) 2007-08-16

Similar Documents

Publication Publication Date Title
CA2500713A1 (en) Photokinetic delivery of biologically active substances using pulsed incoherent light
JP5472770B2 (en) Short melting microneedle
Chen et al. Preparation, properties and challenges of the microneedles-based insulin delivery system
Jamaledin et al. Engineered microneedle patches for controlled release of active compounds: recent advances in release profile tuning
US20070287949A1 (en) Transdermal System for Sustained Delivery of Polypeptides
US10238848B2 (en) Solvent-cast microprotrusion arrays containing active ingredient
KR102114979B1 (en) Micro-spicule, Mold for Producing the Same and Method for Producing the Same
JP2021535928A (en) Implantable sustained release fine needle patch and its preparation method
US20090155330A1 (en) Vaccine Delivery via Microneedle Arrays
CN1897883A (en) Delivery of polymer conjugates of therapeutic peptides and proteins via coated microprojections
EP2691114A1 (en) Delivery of large molecular weight biologically active substances
TW200927199A (en) Gel sheet and cosmetic article using the same
CA2026885C (en) Interface for iontophorese
KR20170000745A (en) Soluble microneedle patch for photosensitizer delivery
JP2006335754A (en) Thin film carrying percutaneous absorption preparation and its manufacturing process
Starlin Chellathurai et al. Biodegradable polymeric insulin microneedles–a design and materials perspective review
CN101160117A (en) Apparatus and method for transdermal delivery of epoetin-based agents
JP2002535293A (en) Methods for enhancing needle-free transdermal powder drug delivery
WO2009050403A2 (en) Patch with hydrophilic adhesive
AU2014200648A1 (en) Solvent-cast microneedle arrays containing active
US20160367791A1 (en) Transdermal System for Sustained Delivery of Polypeptides
KR20200062097A (en) Micro-spicule, Mold for Producing the Same and Method for Producing the Same
Class et al. Patent application title: DELIVERY OF LARGE MOLECULAR WEIGHT BIOLOGICALLY ACTIVE SUBSTANCES Inventors: Julien Janson (Monza, IT) Edward R. Kraft (Galveston, TX, US) Gabriela Kulp (Santa Fe, TX, US) Rosella Malanchin (Cesate, IT) Assignees: PHOTOKINETIX HOLDINGS INC. PRINCIPIUM EUROPE SRL

Legal Events

Date Code Title Description
EEER Examination request
MKEX Expiry

Effective date: 20231003